RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status.


Mutant p53 can exert oncogenic activity by inhibitory interaction with p73. The small-molecule RETRA has been described to disrupt this interaction and to suppress carcinoma cells (Kravchenko et al., 2008). RETRA's anticancer activity was restricted to tumour cells bearing mutant p53; it was not active in p53 negative and in p53 wild-type cells. Here, we… (More)
DOI: 10.1016/j.ejca.2015.02.016


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics